CD79B is a subunit of the B-cell-receptor (BCR) and has been implicated as an oncogenic driver, primarily in activated B-cell (ABC) DLBCL, through mutations that lead to a chronically active state [28]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.